Ensysce Biosciences, Inc. (ENSC) stock
ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.37−0.01 (-3.62%)
Close on Nov 18, 2026Market cap $7.20MP/E –Yield –
Ensysce Biosciences total assets
Total assets on the balance sheet at the end of each period.
Ensysce Biosciences's total assets was $2.96M at Jun 30, 2026. For fiscal 2025 it was $7.45M, up 33.1% from the year before. The highest annual figure on record is $204.83M in fiscal 2018.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.45M | +33.1% |
| FY2024 | Dec 31, 2024 | $5.60M | +106.7% |
| FY2023 | Dec 31, 2023 | $2.71M | -54.0% |
| FY2022 | Dec 31, 2022 | $5.89M | -64.2% |
| FY2021 | Dec 31, 2021 | $16.42M | +4566.6% |
| FY2020 | Dec 31, 2020 | $351.81K | -99.8% |
| FY2019 | Dec 31, 2019 | $196.51M | -4.1% |
| FY2018 | Dec 31, 2018 | $204.83M | +1.2% |
| FY2017 | Dec 31, 2017 | $202.43M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.96M | -46.9% |
| Q1 FY2026 | Mar 31, 2026 | $2.17M | -53.0% |
| Q4 FY2025 | Dec 31, 2025 | $7.45M | +33.1% |
| Q3 FY2025 | Sep 30, 2025 | $3.18M | -66.1% |
| Q2 FY2025 | Jun 30, 2025 | $5.57M | +99.4% |
| Q1 FY2025 | Mar 31, 2025 | $4.61M | -9.1% |
| Q4 FY2024 | Dec 31, 2024 | $5.60M | +106.7% |
| Q3 FY2024 | Sep 30, 2024 | $9.38M | +191.6% |
| Q2 FY2024 | Jun 30, 2024 | $2.80M | -56.0% |
| Q1 FY2024 | Mar 31, 2024 | $5.07M | +29.6% |
| Q4 FY2023 | Dec 31, 2023 | $2.71M | -54.0% |
| Q3 FY2023 | Sep 30, 2023 | $3.22M | -61.2% |
| Q2 FY2023 | Jun 30, 2023 | $6.36M | -20.0% |
| Q1 FY2023 | Mar 31, 2023 | $3.91M | -68.4% |
| Q4 FY2022 | Dec 31, 2022 | $5.89M | -64.2% |
| Q3 FY2022 | Sep 30, 2022 | $8.29M | -14.7% |
| Q2 FY2022 | Jun 30, 2022 | $7.95M | -13.6% |
| Q1 FY2022 | Mar 31, 2022 | $12.37M | -4.7% |
| Q4 FY2021 | Dec 31, 2021 | $16.42M | +4566.6% |
| Q3 FY2021 | Sep 30, 2021 | $9.72M | -26.9% |
| Q2 FY2021 | Jun 30, 2021 | $9.20M | -31.4% |
| Q1 FY2021 | Mar 31, 2021 | $12.98M | -78.9% |
| Q4 FY2020 | Dec 31, 2020 | $351.81K | -99.8% |
| Q3 FY2020 | Sep 30, 2020 | $13.29M | -93.6% |
| Q2 FY2020 | Jun 30, 2020 | $13.41M | -93.5% |
| Q1 FY2020 | Mar 31, 2020 | $61.60M | -70.0% |
| Q4 FY2019 | Dec 31, 2019 | $196.51M | -4.1% |
| Q3 FY2019 | Sep 30, 2019 | $207.21M | +1.6% |
| Q2 FY2019 | Jun 30, 2019 | $206.36M | +1.5% |
| Q1 FY2019 | Mar 31, 2019 | $205.56M | +1.3% |
| Q4 FY2018 | Dec 31, 2018 | $204.83M | +1.2% |
| Q3 FY2018 | Sep 30, 2018 | $204.03M | – |
| Q2 FY2018 | Jun 30, 2018 | $203.23M | – |
| Q1 FY2018 | Mar 31, 2018 | $202.87M | – |
| Q4 FY2017 | Dec 31, 2017 | $202.43M | – |
See a number that looks wrong?